Co-Diagnostics

Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Co-Diagnostics reports Q1 results, focuses on growth and innovation

Co-Diagnostics reported mixed financial results for Q1 2024, with revenue decrease but gross profit increase.
The company is strategically focused on commercialization efforts, product development, and managing expenses for growth.
Despite facing challenges such as net losses and operational complexities, Co-Diagnostics remains optimistic about future opportunities.
With a strong cash position and ongoing FDA submissions, Co-Diagnostics is poised for potential revenue growth and market expansion.

Co-Diagnostics reports Q3 revenue decline, focuses on global expansion

Co-Diagnostics faces financial challenges with a significant net loss in Q3 2024 but maintains a strong focus on advancing its testing platforms and expanding manufacturing capabilities.
Strategic opportunities in international market expansion and test development supported by grants present avenues for growth and market penetration.
Efforts to manage cash position through efficient spending and operational efficiencies underscore the company's commitment to future commercial success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Co-Diagnostics went public in 2017 with a proprietary infectious disease testing technology and a clever strategy. During its early rollout, Co-Diagnostics' strategy failed to generate noticeable revenues.

Co-Diagnostics: A+ Student Faces New Tests

Fulgent Genetics

Johnson & Johnson

Moderna

Novavax

2020 was a wild run for the biotech sector, with COVID-19 dominating the headlines. What will happen this year?

Biotech Stocks: What Will 2021 Look Like?

SALT LAKE CITY, March 10, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Company CEO Dwight Egan will be presenting at the 2nd Annual MarketsandMarkets Infectious Disease Diagnostics and Point-Of-Care Testing Virtual Conference, held March 11-12, 2021. The Conference website states that the event will serve as a networking place for diagnostics professionals, industry specialists, and solution providers to address the rising innovation in point-of-care testing and the way it can be used as a disease prevention tool.

Co-Diagnostics to Present Point-of-Care and At Home Testing Platform at Infectious Disease Diagnostics Virtual Conference

SALT LAKE CITY, March 8, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Company CEO Dwight Egan will present at the 2021 H....

Co-Diagnostics to Discuss Recent Company Advances at H.C. Wainwright Global Life Sciences Virtual Conference

Applied Genetic Technologies

Atomera

Aytu BioScience

Cortexyme Inc

Dynavax Technologies

Sorrento Therapeutics Inc

Getting a big headache watching large-cap S&P 500 stocks lose steam? Small-cap stocks are giving investors a new way to make big money.

7 Small Stocks Up Big Can Still Double From Here, Analysts Say

Co-Diagnostics Inc (NASDAQ:CODX) has announced the development of a new at-home PCR-based coronavirus (COVID-19) testing, screening and surveillance platform that delivers rapid results via smartphone. The small cube-shaped device is designed to perform COVID-19 testing at businesses, schools, homes, hotels, cruise ships, airports, airplanes and other locations.

Co-Diagnostics is designing at-home coronavirus PCR saliva test delivering results by smartphone app

Co-Diagnostics designs at-home coronavirus PCR saliva test delivering results by smartphone app

Walgreens

Co-Diagnostics Inc (NASDAQ:CODX) has confirmed that its patented CoPrimer technology is part of a coronavirus (COVID-19) saliva test that is now available through Walgreens Find Care, a digital health platform on the retailer's website and mobile app. In a statement on Thursday, Dwight Egan, Co-Diagnostics CEO commented: “Co-Diagnostics is proud that our technology will be available on an even more widespread basis following this announcement by our trusted partner CRL, one of the largest privately-held clinical testing laboratories in the U.S.

Co-Diagnostics notes its CoPrimer technology powers coronavirus saliva test now available through Walgreens digital health platform

Its technology underpins a coronavirus test that's about to get much wider distribution.

Why Co-Diagnostics Stock Is Shooting Higher Today

Co-Diagnostics Inc (NASDAQ:CODX) patented CoPrimer technology is part of a coronavirus (COVID-19) saliva test that is now available through Walgreens Find Care, a digital health platform on the retailer's website and mobile app.  The company's COVID-19 RT-PCR test is being sold by Clinical Reference Laboratory under its CRL HealthConfirm brand name for $119 per kit, according to a CRL statement released Wednesday.

Co-Diagnostics' CoPrimer technology powers coronavirus saliva test now available through Walgreens digital health platform

With the latter appointment, the company's founder moves into a more advisory role.

Co-Diagnostics Names New CFO and CSO

Co-Diagnostics Inc (NASDAQ:CODX) announced Tuesday the appointment of Brian Brown as the company's new chief financial officer (CFO). The company said Brown's previous experience includes CFO, vice president of accounting and investor relations, and director of finance roles for public and private companies.

Co-Diagnostics appoints long-time executive Brian Brown as its new chief financial officer

SALT LAKE CITY, Feb. 23, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that it is pleased to welcome Brian Brown, CPA to the position of Co-Diagnostics...

Co-Diagnostics, Inc. Announces New Chief Financial Officer

Co-Diagnostics Inc (NASDAQ:CODX) has said it will be presenting on direct saliva testing for coronavirus (COVID-19) at the 28th Annual International Molecular Medicine Tri-Conference, to be held virtually between February 16-18, 2021. Representatives of the molecular diagnostics specialist will introduce the Co-Diagnostics Logix Smart SARS-CoV-2 DS (Direct Saliva) kit, which the company has submitted for Emergency Use Authorization (EUA) to the US Food and Drug Administration (FDA).

Co-Diagnostics to present on direct saliva testing at Molecular Medicine Tri-Conference

The stock price of Co-Diagnostics Inc (NASDAQ: CODX) is up over 80% over the past month. This is why it happened.

CODX Stock Price Increased Over 80% This Past Month: Why It Happened

The good news is that the end of the pandemic is in sight. The bad news is that it may never really be over.

The Big Picture for Virus Testing Stocks (NASDAQ: FLGT) (OTC US: ALST) (NASDAQ: CODX)

This diagnostic specialist started off the year as a micro cap, but it roared ahead with its COVID-19 test.

Up 938% in 2020, Is Co-Diagnostics Still a Buy in 2021?

SALT LAKE CITY, Jan. 28, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has completed its submission to the U.S. Food...

Co-Diagnostics Completes FDA EUA Submission for Extraction-Free Saliva COVID-19 Test

Beam Global

Blink Charging

Celsius Holdings

Cardiff Oncology

Genprex

GrowGeneration Corp

Kirkland's

Marathon Digital Holdings

Nautilus

Plug Power

Riot Blockchain

AgEagle Aerial Systems

Veritone

Vaxart

Waitr Holdings Inc

This article looks at the 17 companies listed on U.S. exchanges that had a higher total return than high-flying Tesla in 2020. The stocks tended to be microcap to small cap stocks in sectors that piqued investor interest in 2020.

The 17 Stocks That Outperformed Tesla In 2020

This business came into 2020 as an unknown, and now it's generating so much growth it makes even high-profile IPOs look like they're standing still.

Forget Snowflake! Buy This Ultra-High-Growth Stock

Co-Diagnostics is well positioned to benefit from incremental fundamental momentum seen at the back end of 2020. The company's Covid-19 tests are differentiated by distinguishing between common cold and SARS-CoV-2 with an easy to use platform.

Co-Diagnostics: Additional Factors For Consideration In The Investment Debate

GenMark Diagnostics

Natera

Aspira Women’s Health 

These winners are positioned for gains even after COVID.

These Were the 5 Best Diagnostics Stocks of 2020

SALT LAKE CITY, Jan. 7, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Company CEO Dwight Egan will participate in a panel...

Co-Diagnostics to Present at H.C. Wainwright BioConnect 2021 Virtual Conference

SALT LAKE CITY, Jan. 6, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that, based on its preliminary internal financial...

Co-Diagnostics Anticipates Reporting Highest Quarterly Revenue Following Demand for COVID-19 Diagnostic Products

Not all of them were COVID-19 vaccine makers.

These Were the 3 Best Coronavirus Stocks of 2020

News for Co-Diagnostics Stock (CODX)